OLEMA PHARMACEUTICALS, INC. Operating Cash Flow
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Operating Cash Flow of -$91.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$45.90M.
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$45.99M.
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$38.33M.
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$34.53M.
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$146.72M.
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$104.35M.
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$83.73M.
- OLEMA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$82.06M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$45.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$91.88M 10-Q · filed 2026-08-10 | -$130.21M derived: sum of 3 quarters · filed 2026-08-10 | -$164.74M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$45.99M 10-Q · filed 2026-05-12 | -$84.31M derived: sum of 2 quarters · filed 2026-05-12 | -$118.84M derived: sum of 3 quarters · filed 2026-05-12 | -$148.72M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$38.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$72.85M derived: sum of 2 quarters · filed 2026-03-16 | -$102.74M derived: sum of 3 quarters · filed 2026-08-10 | -$146.72M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$34.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$64.41M derived: sum of 2 quarters · filed 2026-08-10 | -$108.39M 10-Q · filed 2025-11-10 | -$134.67M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$29.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$73.86M 10-Q · filed 2026-08-10 | -$100.15M derived: sum of 3 quarters · filed 2026-08-10 | -$127.16M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$43.98M 10-Q · filed 2026-05-12 | -$70.26M derived: sum of 2 quarters · filed 2026-05-12 | -$97.28M derived: sum of 3 quarters · filed 2026-05-12 | -$124.83M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$26.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$53.30M derived: sum of 2 quarters · filed 2026-03-16 | -$80.86M derived: sum of 3 quarters · filed 2026-03-16 | -$104.35M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$27.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$54.57M derived: sum of 2 quarters · filed 2025-11-10 | -$78.07M 10-Q · filed 2025-11-10 | -$96.54M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$27.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$51.05M 10-Q · filed 2025-08-11 | -$69.53M derived: sum of 3 quarters · filed 2025-08-11 | -$92.27M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$23.50M 10-Q · filed 2025-05-13 | -$41.97M derived: sum of 2 quarters · filed 2025-05-13 | -$64.72M derived: sum of 3 quarters · filed 2025-05-13 | -$86.83M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$18.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$41.22M derived: sum of 2 quarters · filed 2025-03-18 | -$63.34M derived: sum of 3 quarters · filed 2025-03-18 | -$83.73M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$22.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$44.86M derived: sum of 2 quarters · filed 2024-11-12 | -$65.25M 10-Q · filed 2024-11-12 | -$84.96M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$22.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$42.51M 10-Q · filed 2024-08-06 | -$62.22M derived: sum of 3 quarters · filed 2024-08-06 | -$80.21M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$20.39M 10-Q · filed 2024-05-08 | -$40.10M derived: sum of 2 quarters · filed 2024-05-08 | -$58.09M derived: sum of 3 quarters · filed 2024-05-08 | -$84.55M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$19.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$37.70M derived: sum of 2 quarters · filed 2024-03-11 | -$64.16M derived: sum of 3 quarters · filed 2024-03-11 | -$82.06M 10-K · filed 2024-03-11 |
| 2022-09-30 | -$17.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$44.45M derived: sum of 2 quarters · filed 2023-11-07 | -$62.35M 10-Q · filed 2023-11-07 | -$80.96M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$26.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$44.36M 10-Q · filed 2023-08-08 | -$62.97M derived: sum of 3 quarters · filed 2023-08-08 | -$75.06M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$17.90M 10-Q · filed 2023-05-09 | -$36.51M derived: sum of 2 quarters · filed 2023-05-09 | -$48.60M derived: sum of 3 quarters · filed 2023-05-09 | -$57.51M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$18.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$30.70M derived: sum of 2 quarters · filed 2023-03-09 | -$39.61M derived: sum of 3 quarters · filed 2023-03-09 | -$50.69M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$12.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$21.00M derived: sum of 2 quarters · filed 2022-11-08 | -$32.09M 10-Q · filed 2022-11-08 | -$41.10M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$8.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$19.99M 10-Q · filed 2022-08-09 | -$29.00M derived: sum of 3 quarters · filed 2022-08-09 | -$36.54M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$11.08M 10-Q · filed 2022-05-09 | -$20.10M derived: sum of 2 quarters · filed 2022-05-09 | -$27.63M derived: sum of 3 quarters · filed 2022-05-09 | -$28.81M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$9.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$16.55M derived: sum of 2 quarters · filed 2022-02-28 | -$17.73M derived: sum of 3 quarters · filed 2022-02-28 | -$19.87M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$7.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$8.72M derived: sum of 2 quarters · filed 2021-11-10 | -$10.85M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$3.32M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$2.14M 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | -$3.08M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |